Physician profile
Sandra C Edwards
NPI 1609059278
$1,559.68
in general payments reported to CMS, 2019-2025
12 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,215 · 2022: $344.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,005.96 | 2021-2022 | |
| Eisai INC. | $192.64 | 2021 | |
| Pfizer INC. | $143.47 | 2021-2022 | |
| Ironwood Pharmaceuticals, INC | $67.93 | 2021 | |
| Myovant Sciences INC. | $32.24 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $29.32 | 2021 | |
| Virtus Pharmaceuticals LLC | $17.29 | 2021 | |
| Horizon Therapeutics Plc | $15.73 | 2021 | |
| Urovant Sciences INC | $15.23 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $14.39 | 2021 | |
| Scynexis, INC. | $13.71 | 2022 | |
| Bausch Health US, LLC | $11.77 | 2021 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sandra Edwards listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.